Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

The listing of claims will replace all prior versions, and listings, of claims in this application.

1. (**Original**) The use of a peptide comprising all or an immunogenic part of the amino acid sequence designated SEQ ID NO 6 in the manufacture of a vaccine to stimulate an anti-cancer immune response against COA-I (SEQ ID NO 2), wherein the immunogenic part of the sequence is processed and expressed by antigen presenting cells in association with sympathetic MHC class II molecules.

2. (**Currently amended**) Use according to claim 1, wherein the ~~inununogenic~~ immunogenic part of the sequence comprises 8 or more contiguous amino acid residues of SEQ ID NO 6.

3. (**Original**) Use according to claim 2, wherein the immunogenic part of the sequence comprises 10 or more contiguous amino acid residues of SEQ ID NO 6.

4. (**Currently amended**) Use according to claim 1, wherein the immunogenic part of the sequence further comprises SEQ ID NO 9 at the N-terminus and/or SEQ ID NO 10 at the C- terminus.

5. (**Original**) Use according to claim 1, wherein the immunogenic part of the sequence consists of SEQ ID NO 6.

6. (**Previously amended**) Use according to claim 1, wherein the immune response is stimulated against Colorectal Cancer cells.

7. (**Previously amended**) Use according to claim 1, wherein the peptide is an oligopeptide.

8. (**Original**) Use according to claim 1, wherein the MHC class II molecules are the HLA DRβ1*0402 and/or HLA DRβ1*1301 alleles.

9. (**Previously amended**) Use according to claim 1, wherein the vaccine further comprises PBMC's (Peripheral Blood Mononuclear Cells) either expressing the HLA DRβ1*0402 and/or HLA DRβ1*1301 alleles.

10. (**Previously amended**) Use according to claim 1, wherein the vaccine further comprises Dendritic cells, pulsed with a peptide comprising all or an immunogenic part of the amino acid sequence designated SEQ ID NO 6 or transfected with polynucleotides encoding said peptide, the Dendritic cells either expressing the HLA DRβ1*0402 and/or HLA DRβl*1301 alleles.

11. (**Currently amended**) A vaccine comprising a peptide, ~~as defined in claim 1~~ wherein the peptide comprises a portion consisting of all or an immunogenic part of the amino acid sequence set forth in SEQ ID NO 6, where said portion is sufficient to stimulate an anti-cancer immune response against COA-I (SEQ ID NO 2), and wherein the immunogenic part of the sequence is processed and expressed by antigen presenting cells in association with sympathetic MHC class II molecules.

12. (**Currently amended**) A vaccine according to claim 11 further comprising a suitable carrier.

13. (**Currently amended**) A vaccine according to claim 11, comprising the peptide and PBMC's expressing a sympathetic MHC Class II allele therefor.

14. (**Original**) A vaccine according to claim 13, wherein the MHC Class II allele is the HLA DRβ1*0402 and/or HLA DRβ1*1301 allele.

15. (**Previously amended**) A method for stimulating immunity in a patient against colorectal cancer, comprising stimulating the production of antibodies against a peptide, as defined in claim 1.

16. (**Original**) A method according to claim 15, wherein immunity is stimulated in the patient in conjunction with PBMC's allogeneic or autologous for at least one sympathetic HLA.-II allele capable of presenting all or an immunogenic part of the amino acid sequence designated SEQ ID NO 6 in an immunogenic manner.

17. (**Original**) A method according to claim 16, wherein the allele is selected from HLA DRβ1*0402 and/or HLA DRβ1*1301.

18. (**Previously amended**) A method according to claim 15, wherein the patient has PBMC'S autologous or allogeneic for at least one sympathetic HLA-II allele capable of presenting the COA-1 epitope in an immunogenic manner, the method comprising administering a vaccine comprising the immunising portion of COA-1, or a precursor therefor, to the patient.

19. (**Previously amended**) A method for stimulating immunity to colorectal cancer in a patient, said method comprising:

i) isolating PBMC's or their progenitors from the patient and transforming said cells with at least one sympathetic HLA-II allele capable of presenting the COA-1 epitope in an immunogenic manner,

ii) introducing the transformed PBMC's back into the patient, and

iii) administering a vaccine comprising the immunising portion of COA-1, or a precursor therefor, as defined in claim 1, to the patient.

20. (**Original**) A method according to claim 19, wherein the immunising portion of COA-1 or a precursor therefor, is administered with the transformed PBMC's.

21. (**Previously amended**) Use according to claim 1, wherein the immune response is stimulated against melanoma cells.